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ABSTRACT
Objective Transcribed-ultraconserved regions (T-UCR)
are long non-coding RNAs which are conserved across
species and are involved in carcinogenesis. We studied
T-UCRs downstream of the Wnt/β-catenin pathway in
liver cancer.
Design Hypomorphic Apc mice (Apcﬂ/ﬂ) and
thiocetamide (TAA)-treated rats developed Wnt/β-catenin
dependent hepatocarcinoma (HCC) and
cholangiocarcinoma (CCA), respectively. T-UCR
expression was assessed by microarray, real-time PCR
and in situ hybridisation.
Results Overexpression of the T-UCR uc.158− could
differentiate Wnt/β-catenin dependent HCC from normal
liver and from β-catenin negative diethylnitrosamine
(DEN)-induced HCC. uc.158− was overexpressed in
human HepG2 versus Huh7 cells in line with activation of
the Wnt pathway. In vitro modulation of β-catenin altered
uc.158− expression in human malignant hepatocytes.
uc.158− expression was increased in CTNNB1-mutated
human HCCs compared with non-mutated human HCCs,
and in human HCC with nuclear localisation of β-catenin.
uc.158− was increased in TAA rat CCA and reduced after
treatment with Wnt/β-catenin inhibitors. uc.158−
expression was negative in human normal liver and biliary
epithelia, while it was increased in human CCA in two
different cohorts. Locked nucleic acid-mediated inhibition
of uc.158− reduced anchorage cell growth, 3D-spheroid
formation and spheroid-based cell migration, and
increased apoptosis in HepG2 and SW1 cells. miR-193b
was predicted to have binding sites within the uc.158−
sequence. Modulation of uc.158− changed miR-193b
expression in human malignant hepatocytes. Co-
transfection of uc.158− inhibitor and anti-miR-193b
rescued the effect of uc.158− inhibition on cell viability.
Conclusions We showed that uc.158− is activated by
the Wnt pathway in liver cancers and drives their growth.
Thus, it may represent a promising target for the
development of novel therapeutics.
BACKGROUND
Hepatocellular carcinoma (HCC) is the sixth most
common malignancy in the world.1 Despite the
progress of recent decades, the outcome of patients
with advanced HCC remains poor, and mortality
for liver cancer has increased worldwide.1
Sorafenib is the only drug which is effective in
advanced HCC with an improvement of about
3 months in median overall survival.2 Novel therap-
ies are urgently needed, but their development is
Summary box
What is already known on this subject?
▸ The Wnt/β-catenin pathway is frequently
activated in liver cancer. The understanding of
the molecular mechanisms of Wnt deregulation
is necessary to develop more speciﬁc and
effective therapeutics.
▸ Transcribed-ultraconserved regions (T-UCRs) are
long non-coding RNAs that harbour
ultraconserved elements and are altered in
human carcinomas.
What are the new ﬁndings?
▸ We demonstrate that T-UCRs are downstream
mediators of the Wnt/β-catenin pathway in
three different species, and we provide
evidence of their role as competing
endogeneous long non-coding RNAs.
▸ We have identiﬁed a mediator that is
downstream of the Wnt/β-catenin pathway and
speciﬁc for cancer development, improving the
development of effective and selective novel
therapeutics.
How might it impact on clinical practice in
the foreseeable future?
▸ We have studied several cohorts of human liver
cancers and observed that deregulation of
uc.158− is shared between hepatocarcinoma
and cholangiocarcinoma, providing interesting
insights into the molecular biology of these
diseases and the implication for clinical trial
design.
Carotenuto P, et al. Gut 2016;0:1–10. doi:10.1136/gutjnl-2016-312278 1
GI cancer
challenged by the limited understanding of the molecular
mechanisms underlying HCC progression and the subsequent
lack of identiﬁed targets that drive liver transformation.
The Wnt pathway is frequently activated in HCC.3 4 Various
attempts have been made to develop therapeutics targeting the
Wnt pathway components, and some of these are now under
clinical evaluation.5 However, the challenges faced in the devel-
opment of Wnt inhibitors, such as speciﬁcity and toxicity,
demand a better understanding of the molecular mechanisms
involved in Wnt deregulation, in order to inform the design of
more speciﬁc and more effective compounds. The canonical
Wnt pathway (or Wnt/β-catenin pathway) leads to an accumula-
tion of β-catenin in the cytoplasm that can be translocated into
the nucleus and activate transcription factors.3 A recent analysis
of human HCC has shown that the Wnt pathway is activated in
49% of HCC and that almost half of these had features consist-
ent with the activation of the Wnt/β-catenin pathway.6 These
data are in line with an integrated analysis of somatic mutations
which revealed activating mutations of β-catenin (CTNNB1) in
33% of human HCC. In addition, mutations of CTNNB1 are
mutually exclusive with mutations in AXIN1.7
Non-coding RNAs (ncRNA) are implicated in liver carcino-
genesis.8–10 We and others have provided data to support the
involvement of small ncRNAs, such as microRNAs, in the
modulation of liver cell proliferation and apoptosis.10–13
Despite several studies linking ncRNA and the Wnt pathway,
most of them focused on the modulation of Wnt signalling pro-
teins by microRNAs, little is known about the effect of this
pathway on ncRNA.14–17 Increasing evidence points to an
important regulatory role of long ncRNAs in cellular processes
and disease phenotypes. Sequence conservation across species
has been postulated to indicate that a given ncRNA may have a
cellular function. A genome-wide survey identiﬁed 481 genomic
sequences with a size >200 bp that showed a remarkable con-
servation with 100% identity across human, mouse and rat
genomes.18 These ultraconserved regions (UCR) were shown to
be transcribed as ultraconserved ncRNAs (T-UCR). They exhibit
distinct proﬁles in various human cancers and modulate cellular
proliferation and apoptosis.19–25 We have previously shown that
T-UCRs are aberrantly expressed in HCC and have a role in the
malignant growth of human and murine hepatocytes.25 In this
study, we aim to investigate the effect of Wnt/β-catenin signal-
ling on T-UCRs in order to ﬁnd downstream effectors of this
pathway that can be targeted for the development of novel and
more speciﬁc therapeutics.
METHODS
Animal models
All animals were handled in strict accordance with good animal
practice as deﬁned by the relevant national and/or local animal
welfare bodies, and all animal works were approved by the
appropriate committees. Experiments were carried out in com-
pliance with UK Home Ofﬁce Animal (Scientiﬁc Procedures)
Act 1986 and the EU Directive 2010. Hypomorphic mutant
(Apc580s/580s) Apcﬂ/ﬂ mice were used and compared with Apc
+/+ mice. Model generation and demonstration of the activa-
tion of Wnt/β-catenin pathway in this HCC model have already
been reported.26 We extracted RNA from the liver of Apcﬂ/ﬂ
(tumour with activation of Wnt/β-catenin) and Apc+/+ (normal
liver). TAA rat tumour model was used as a model of rat cholan-
giocarcinoma (CCA). Generation of this model and activation of
Wnt pathway in this tumour model have already been
reported.27 ICG-001 (5 mg/kg) (Tocris, Bristol, UK) or C-59
(20 mg/kg) (Cellagen Technologies, San Diego, California, USA)
was given by intraperitoneal injection. The vehicle for this was
physiological saline (Sigma-Aldrich, Sigma, St Louis, Missouri,
USA). Control animals were given vehicle alone. In all cases,
inhibitors and vehicle were given three times per week.27 We
extracted RNA from the liver of TAA rat (tumour) or saline
control (normal liver), as well as from TAA rats treated with
ICG-001, C59 or saline control. Axin1ﬂ/ﬂ/Cre mouse model
was used to investigate the effect of Axin1 disruption in the
hepatocytes. This model was generated by crossing mice homo-
zygous for the Axin1ﬂ/ﬂ allele with AhCre mice, as previously
reported.28 We extracted RNA from the liver of Axin1ﬂ/ﬂ/Cre
and Axin1+/+/Cre mice. Diethylnitrosamine-induced HCC:
C57BL/6, 14 days old male mice were intraperitoneally injected
with diethylnitrosamine (DEN) (40 μL of a solution containing
10 mg/mL DEN in PBS:80 mg/kg). Mice were sacriﬁced at
36 weeks after DEN injection; liver was assessed for macro-
scopic tumour number and size, and normal liver and tumour
samples were placed into RNA later, snap-frozen in liquid nitro-
gen or ﬁxed in neutral buffered formalin overnight at 4°C for
the assessment of β-catenin.
Rapid Apc inactivation in Apcﬂ/ﬂ mice
To investigate the phenotype of conditional deletion of Apc,
AhCre+Apcﬂ/ﬂ and AhCre+Apc+/+ progeny were used as pre-
viously described.29 Mice were given daily intraperitoneal injec-
tions of β-napthoﬂavone (80 mg/kg) as previously reported.30
After 4 days, mice were killed and liver removed, weighed and
placed into RNA later (Sigma, St Louis, Missouri, USA) or ﬁxed
in formalin. For BrdU labelling, mice were injected with
0.25 mL of BrdU (GE Healthcare, Amersham, UK), 2 hours
prior to sampling, and staining was performed using an
anti-BrdU antibody conjugate (#347580, BD Biosciences, San
Jose, California, USA; 1:150). Staining for mouse β-catenin was
performed on sections from tissue samples ﬁxed at 4°C for
<24 hours in 10% formalin prior to processing using the anti-
body (#610154, BD Biosciences; 1:50).
T-UCR expression proﬁling in mice
RNA from the liver of Apcﬂ/ﬂ (n:3), Apc+/+ (n:3) and
DEN-treated mice (n:3) were used. mRNA was puriﬁed from
total RNA after removal of rRNA (mRNA-ONLY Eukaryotic
mRNA Isolation Kit, Epicentre, Madison, Wisconsin, USA).
Then, each sample was ampliﬁed and transcribed into ﬂuores-
cent cRNA along the entire length of the transcripts without 30
bias, using a random priming method. The labelled cRNAs were
hybridised onto the mouse LncRNA Array V.2.0 (Arraystar,
Rockville, Maryland, USA), which also included probes for
protein-coding RNAs. The arrays were scanned by the Agilent
Scanner G2505C (Agilent Technologies, Santa Clara, California,
USA). Agilent Feature Extraction software (V.11.0.1.1) was used
to analyse the acquired array images. Quantile normalisation
and subsequent data processing were performed using the
GeneSpring GX V.11.5.1 software package (Agilent
Technologies). After quantile normalisation of the raw data, dif-
ferentially expressed LncRNAs with statistical signiﬁcance
between groups (Apcﬂ/ﬂ vs Apc+/+; Apcﬂ/ﬂ vs DEN-HCC)
were identiﬁed through volcano plot ﬁltering, with a threshold
fold change ≥2.0 and p≤0.05.
Human tissues
The human CCA tissues were collected under approval of the
Ethical Committee for Clinical Research of Padua and the
University of Edinburgh ethics committee. Healthy liver was
provided by the NHS Scotland Research (NRS) BioResource,
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NHS Lothian. All tissues were collected with informed consent.
HCC tissues were provided by the University Hospital Basel and
University of Ferrara after appropriate ethical approval. For the
CCA tissue microarray (TMA), a retrospective series (1990–
2011) of 102 surgically resected primary biliary cancers, includ-
ing 85 CCA and 17 gall bladder carcinoma specimens, were
retrieved from the formalin-ﬁxed parafﬁn-embedded (FFPE)
archives of the Department of Pathology and Diagnostics and the
ARC-NET biobank of the University and Hospital Trust of
Verona after appropriate ethical approval. CCAs were classiﬁed
according to WHO 2010 as intrahepatic cholangiocarcinoma
(ICC, n=54) and extrahepatic cholangiocarcinoma (ECC; n=31).
Five 1 mm core TMAs were assembled. Additional 14 non-
neoplastic controls were included in the TMAs. Three tissue
cores per case were analysed.
Statistical analysis
Statistical analyses were performed by GraphPad Prism 6 (La
Jolla, California, USA). Results are expressed as mean±SD,
unless indicated otherwise. Groups that were normally distribu-
ted were compared with either a two-tailed Student’s t-test (for
analysis of two groups) or using one-way analysis of variance to
compare multiple groups. Non-parametric data were analysed
using a Wilcoxon-Mann-Whitney U test when comparing two
groups. Signiﬁcance was accepted when p<0.05. *p:0.05–0.01;
**p:0.009–0.001; ***p<0.001.
Additional methods can be found in the online supplementary
information, along with the primer sequences (see online
supplementary table S1).
RESULTS
T-UCR proﬁling in HCC mouse models
Hypomorphic Apc mice (Apcﬂ/ﬂ) were previously shown to
develop HCC with activation of the Wnt/β-catenin pathway
(nuclear localisation of β-catenin and activation of Wnt-related
genes).26 To assess T-UCRs downstream of the Wnt pathway, we
proﬁled ncRNA expression by microarray in the liver of Apcﬂ/ﬂ
and control Apc+/+ mice. Twenty-two T-UCRs were aberrantly
expressed (ﬁgure 1A, see online supplementary table S2), with
four upregulated and eighteen downregulated, greater than
twofold, in tumour tissues from APCﬂ/ﬂ compared with normal
liver from Apc+/+. To verify if these T-UCRs were speciﬁcally
altered by Wnt/β-catenin or just affected by the malignant trans-
formation, we proﬁled T-UCR expression in the livers of mice
treated with DEN, which developed a median of 17 (range:
13–36) tumours per liver with no nuclear activation of β-catenin
(see online supplementary ﬁgure S1). Interestingly, we found
that four T-UCRs could further differentiate Apcﬂ/ﬂ-HCC from
DEN-induced HCC (ﬁgure 1A, see online supplementary table S3).
Expression of uc.158−, uc.455+, uc.196+ and uc.82− was
assessed by real-time PCR in the liver tissues of a second series
of Apcﬂ/ﬂ and control Apc+/+ mice (ﬁgure 1B). uc.158− and
uc.455+ were conﬁrmed to be signiﬁcantly upregulated and
downregulated, respectively, in Wnt-dependent HCC. uc.158−
is an intergenic 224 nt long UCR located on chromosome 13
in the mouse and on chromosome 5 in the human genome.
uc.455+ is a 245 nt long UCR located on chromosome 2 in the
mouse and on chromosome 20 in the human genome, where it
overlaps in antisense the RNA-binding protein motif 39
(RBPM39) gene. Given the fact that uc.158− does not overlap
protein-coding genes, and that intergenic lncRNAs have been
shown to be more stable,31 we focused on uc.158− for further
studies.
Uc.158− expression is downstream of Wnt signalling in
human liver cancer cells
To understand the human relevance of previous ﬁndings, we
assessed the expression of uc.158− in human malignant hepato-
cytes. HepG2 cells are known to harbour mutations in exon 3
of the β-catenin gene (CTNNB1), while Huh-7 cells are known
to be wild type (WT) for CTNNB1 and other genes of the Wnt
pathway.6 The Wnt pathway is activated in HepG2 cell lines,
but not in Huh-7, in line with the mutational status of these
cells (see online supplementary table S4 and ﬁgure S2A, B).
Global lncRNA expression analysis revealed that uc.158− is
increased in malignant hepatocytes in comparison with normal
human hepatocytes and that overexpression is greater in HepG2
than in Huh-7 (see online supplementary ﬁgure S2C). We then
extended our studies to a panel of malignant hepatocytes.
Immunoﬂuorescence showed that β-catenin localises in the
Figure 1 Transcribed-ultraconserved regions (T-UCR) proﬁling in an Apc hypomorphic hepatocarcinoma (HCC) mouse model. (A) T-UCRs aberrantly
expressed in Apcﬂ/ﬂ (n:3) versus control Apc+/+ (n:3) mice livers. Fold change has been plotted against p values, with lowest p values being on the
top of the y-axis. T-UCRs highlighted in red are those that were common across the two proﬁling comparing Apcﬂ/ﬂ versus Apc+/+ and comparing
Apcﬂ/ﬂ versus diethylnitrosamine (DEN)-induced HCC (n:3). (B) Validation of T-UCR expression by real-time PCR. Bars represent mean±SD of four
samples.
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nuclei of HepG2 cells and Hep-3B, although to a lesser extent
(ﬁgure 2A), as previously described.32 Interestingly, the expres-
sion of uc.158− reﬂects this ﬁnding, with the highest expression
being in HepG2 (ﬁgure 2B). PLC/PRF-5 cells had a very low
expression of uc.158− and did not show localisation of
β-catenin despite their mutation in AXIN133 (ﬁgure 2A, B).
To further study this ﬁnding, we analysed the expression of
uc.158− in the liver of mice genetically engineered to harbour
deletion of Axin1. These animals (Axin1ﬂ/ﬂ/Cre) were shown to
develop microscopic foci of HCC in the absence of nuclear
localisation of β-catenin.28 In line with previous ﬁndings, we did
not detect any change in the expression of uc.158− in the liver
of Axin1ﬂ/ﬂ/Cre in comparison with WT mice (ﬁgure 2C).
To further validate the dependency of uc.158− on the Wnt/
β-catenin pathway, we assessed its expression after modulation
of β-catenin in vitro. Treatment of Huh-7 cells with LiCl
induced activation of β-catenin and an increase in the expression
of uc.158− (ﬁgure 2D). Inhibition of β-catenin by siRNA or by
Figure 2 uc.158− expression is
dependent on Wnt/β-catenin pathway
in human malignant hepatocytes. (A)
Immunoﬂuorescence was performed
for β-catenin (CTNNB1) and Hoechst in
a panel of malignant hepatocytes.
Scale bar: 50 μm (B) Expression of
uc.158− was assessed in the same
panel of malignant hepatocytes by
real-time PCR. Bars represent mean
±SD of three independent samples.
(C) uc.158− expression was assessed
by real-time PCR in the liver of
wild-type (WT) and Axin1ﬂ/ﬂ/Cre mice.
Bars represent mean±SD of six
samples. p>0.05. (D) Huh-7 cells were
treated with 25 mM LiCl or diluent
control for 24 hours and cells collected
to assess induction of β-catenin
protein expression by western blotting,
induction of nuclear localisation by
immunoﬂuorescence and expression of
uc.158− by real-time PCR. Bars
represent mean±SD of three
experiments. (E) HepG2 cells were
transfected with siRNA against
CTNNB1 (siCTNNB1) or siRNA CTRL
(50 nM) for 48 hours, and cells
collected to assess reduction in
expression of CTNNB1 mRNA, protein
expression and expression of uc.158−
by real-time PCR. Bars represent mean
±SD of three experiments. (F) HepG2
cells were treated with 50 μM ICG-001
for 24 hours, and cells collected to
assess downregulation of drug-target
mRNAs and expression of uc.158− by
real-time PCR. Bars represent mean
±SD of three experiments.
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the Wnt/β-catenin inhibitor ICG-001 induced a decrease in the
expression of uc.158− in HepG2 cells (ﬁgure 2E, F).
Uc.158− expression in human HCC tissues
We have previously shown that T-UCRs are transcribed as inde-
pendent transcripts which are longer than the UCRs described
by Bejerano.25 To characterise the 50-end of the transcript
including uc.158−, we performed a rapid ampliﬁcation of
cDNA ends (RACE). We have shown that uc.158− is transcribed
in antisense and that the 5-end is characterised by additional
306 nucleotides upstream of the known uc.158− (see online
supplementary ﬁgure S3). To conﬁrm the transcript is tran-
scribed in antisense, we performed in situ hybridisation in FFPE
human liver tissues. We used three different probes: S1 which
recognised the sense uc.158+ and AS1 and AS3 which both
could detect the antisense uc.158−. In line with our RACE
experiments, S1 did not show any signal, conﬁrming that
uc.158− is transcribed in antisense (see online supplementary
ﬁgure S3). We next analysed a series of human FFPE liver
tissues. Cirrhotic tissues were negative for uc.158− expression,
while HCC tissues were positive. However, it is of note that
HCC with negative or membranous expression of β-catenin by
immunohistochemistry (IHC) had a weak/moderate cytoplasmic
expression, while liver tumours with nuclear β-catenin showed
the most intense signal (ﬁgure 3A, see online supplementary
table S5). Next, we studied a second cohort of human frozen
HCCs where CTNNB1, APC and AXIN1 genes were analysed
by sequencing (as previously described34). The median expres-
sion of uc.158− was signiﬁcantly higher in the mutated group
(which included six CTNNB1-mutated and one APC-mutated
HCC) than in WT controls (ﬁgure 3B). However, isolated WT
HCCs showed an increased expression of uc.158−, suggesting
that in rare cases the source of uc.158− may be alternative to
the mutations studied. Indeed, hepatitis liver tissues showed
negative non-neoplastic hepatocytes and positive lymphocytes
(see online supplementary ﬁgure S4A), suggesting that the
stroma may represent a source of uc.158−. To understand if
uc.158− is speciﬁc to malignant cells or can be expressed also in
non-tumour hepatocytes, we looked at uc.158− expression in
the liver of a mouse model with conditional Apc deletion
(AhCre+Apcﬂ/ﬂ), which presents an increase in liver weight and
proliferation, but not tumours. Indeed, we noticed that uc.158−
expression was not changed following activation of the Wnt/
β-catenin pathway in absence of cancer (ﬁgure 4).
Figure 3 uc.158− expression in human hepatocarcinoma (HCC) tissues. (A) Formalin-ﬁxed parafﬁn-embedded human liver tissues have been
analysed for the expression of uc.158− by RNA in situ hybridisation and for CTNNB1 protein expression by immunohistochemistry. Scale bars:
200 μM for the top and bottom line, 50 μM for the second line. (B) DNA and RNA were extracted from 15 frozen HCC tissues and used for uc.158−
expression by real-time PCR and sequencing analysis for APC, AXIN1 and exon 3 of CTNNB1. The circled orange dot represents a case with
mutation of APC. Bars represent median with IQR. Mann-Whitney test, exact two-tailed p value: 0.04.
Figure 4 Apc deletion does not
induce uc.158− in the absence of
tumour. Conditional Apc deletion
induced by β-napthoﬂavone injection
in AhCre+Apc+/+ and AhCre+Apcﬂ/ﬂ
mice on day 1. Mice (n=3 for each
group) were euthanised on day 4, and
liver weighed and processed for
downstream analyses. (A) IHC analysis
for CTNNB1 and BrDU. Scale bar:
10 μM (B) Liver weight is expressed as
percentage of the whole body weight
(median and range). (C) Expression of
uc.158− (median and range).
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Uc.158− in CCA
Recent evidence has shown that CCA, another form of primary
liver cancer, is dependent on the Wnt pathway despite the lack
of CTNNB1 mutations in malignant cholangiocytes.27 35–37 In
order to understand if our ﬁndings were disease-speciﬁc or
could be extended also to CCA, we looked at uc.158− expres-
sion in an initial cohort of British human intrahepatic CCAs
(ICC) and found that uc.158− was signiﬁcantly overexpressed
in tumour tissues compared with healthy livers (ﬁgure 5A).
Interestingly, uc.158− was increased in CCA compared with
normal tissues in all four cases for which matched adjacent
tissues were available (ﬁgure 5B). These data were conﬁrmed in
another series of Italian CCA by in situ hybridisation. We
studied the expression of uc.158− using a TMA including 54
ICC, 31 extrahepatic CCA (ECC) and 17 gall bladder cancers
(GBC), along with additional 8 normal biliary ducts and liver
parenchyma and 6 liver tissues adjacent to CCA (see online
supplementary table S6). Normal biliary epithelia and liver par-
enchyma were always uc.158− negative. High uc.158− expres-
sion (++/+++) was detected in 74% of ICC, 58% of ECC
and 24% of GBC (ﬁgure 5C, see online supplementary table
S6). Adequate paired tumoural and adjacent non-tumoural
tissues for analysis were available from six cases, and in all of
them uc.158− was overexpressed. Interestingly, the perilesional
adjacent liver was rarely negative, and most of them showed
weak/moderate positivity, suggesting that uc.158− may be
involved in the carcinogenic process (see online supplementary
ﬁgure S5). Stromal cells were strongly positive (see online
supplementary ﬁgure S4B), in accordance with data by Boulter
et al27 showing that the stroma is one of the sources of Wnt in
CCA. To further investigate these ﬁndings, we studied a rat
model of thiocetamide (TAA)-induced CCA, which appropri-
ately models ICC on a background of inﬂammation and activa-
tion of β-catenin, as previously shown.27 uc.158− expression
was increased in tumour tissues compared with control livers,
conﬁrming that uc.158− deregulation is conserved across
species along with the sequence (ﬁgure 5D). To further prove
the dependency on the Wnt pathway, we analysed the expres-
sion of uc.158− after treatment with two different Wnt inhibi-
tors. ICG-001 reduced expression of uc.158− by 52%, while
C-59 decreased uc.158− expression to almost undetectable
levels in rat CCA (ﬁgure 5E).
Figure 5 uc.158− expression in cholangiocarcinoma. (A) RNA was extracted from frozen intrahepatic cholangiocarcinoma (CCA) (n: 5) and normal
liver (n:8) tissues and assessed for uc.158− expression by real-time PCR. Bars represent mean±SE. (B) In four cases, CCA and matched adjacent
tissues from the same patients were available. Bars represent uc.158− expression in tumour tissue relative to the expression in the adjacent normal
tissue. Fold change tumour/normal (T/N) is reported for each case on the top of the bars. (C) A tissue microarray of formalin-ﬁxed
parafﬁn-embedded human tissues including 54 intrahepatic cholangiocarcinoma (ICC), 31 extrahepatic cholangiocarcinoma (ECC), 17 gallbladder
cancers (GBC) and 8 normal liver tissues was assessed for expression of uc.158− by RNA in situ hybridisation (ISH) with AS3 probe. Pictures of
representative cases are shown. (D) RNA was extracted from the liver of thiocetamide (TAA)-treated (with CCA) or vehicle-treated (normal) rats for
26 weeks and analysed for uc.158− expression by real-time PCR. Bars represent mean±SD of three samples. (E) Rats with TAA-induced CCA were
treated with the CTNNB1-CTBP inhibitor ICG-001 (5 mg/kg) or PORCN inhibitor C-59 (20 mg/kg) or saline vehicle by intraperitoneal injection three
times per week, from week 21 to 26. At 26 weeks, rats were sacriﬁced, and uc.158− expression assessed by real-time PCR. Bars represent mean±SD
of four samples.
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Biological relevance of uc.158−
To gain insights into the biological relevance of uc.158−, we
studied phenotypical changes induced by inhibition of uc.158−
in HepG2 cells. We tested four different locked nucleic acid
probes (GAPMER, GAP1-4) speciﬁcally designed to interact
with the conserved sequence of uc.158−. GAP1 and GAP3 pro-
vided the best inhibition (see online supplementary ﬁgure S6)
and therefore were selected for further experiments. Cell
growth was reduced by 60% and 70% at 72 hours in HepG2
cells transfected with GAP1 and GAP3, respectively, compared
with the control (CTRL) probe (ﬁgure 6A). To better under-
stand the mechanism through which cell viability is affected, we
ran a cell cycle analysis after transfection, and noticed that there
were no changes in the progression through the cell cycle
phases, but for an increased accumulation of cells in the
sub-GO/1 phase (potentially apoptotic) in cells transfected with
Figure 6 uc.158− inhibition reduces
cancer cell growth. (A) HepG2 cells
were reverse-transfected with GAPMER
probes anti-uc.158− GAP1 and GAP3
or control-scrambled probe (CTRL) in
96 well plates, and cell viability
assessed by CellTiter-Blue after
72 hours. Non-transfected (untreated)
cells were added as control for
transfection toxicity. Representative
pictures and quantiﬁcation of seven
replicates with mean±SD are
represented. Scale bar: 400 μM. (B)
HepG2 cells were transfected, and
analysis of cell-cycle distribution was
performed by ﬂow cytometry.
Quantiﬁcation of three experiments
(mean±SD) is shown on the left. The
representative picture on the right
shows peaks for cells transfected with
CTRL, GAP1 and GAP3 probes. In the
red square, representative zoom of the
sub-G0/G1 peak. (C) HepG2 cells were
reverse-transfected in 96 well plates,
and activation of caspase 3/7 was
assessed by luminescence assay.
Staurosporine was added as positive
control. Bars represent mean±SD of
three replicates. Asterisks indicate p
value by t-test analysis. Analysis of
variance comparison was performed
comparing all the groups, or only the
three experimental groups (CTRL,
GAP1, GAP3), with the following
results: p:0.0004 and p:0.0012,
respectively, at 6 hours; p<0.0001 for
both comparisons at 24 hours. (D)
HepG2 cells were transfected with
GAPMER probe anti-uc.158− GAP1 or
CTRL-scrambled probe and then ﬁxed
in formalin and embedded in parafﬁn.
Immunohistochemistry was then
performed for caspase
3. Representative pictures of two
independent experiments are shown.
(E) HepG2 cells were
reverse-transfected with anti-uc.158−
GAP1 and GAP3 or control probe in
100 mm dishes and then plated in
ultra low attachment (ULA) 96-well
plates to form spheroids. Imaging and
quantitation were performed after
7 days with Celigo. Bars represent
mean±SD of six replicates. (F) Once
the spheroids were formed, they were
moved to ﬂat-bottom, gelatin-coated
96-well plates, and migration was
assessed at different time points
through Celigo.
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GAP1 and GAP3 (ﬁgure 6B). Indeed, we observed an increase
in the activated caspase 3/7 by luminescence (ﬁgure 6C) with no
increase in necrosis (see online supplementary ﬁgure S7).
Increase in the expression of caspases and cleaved poly ADP
ribose polymerase (PARP) was also noted after uc.158− silen-
cing (ﬁgure 6D, see online supplementary ﬁgure S8).
Anchorage-independent growth was assessed by tumour 3D
spheroid assay. The volume of 3D spheroid generated from
HepG2 cells transfected with GAP 1 and GAP3 was reduced to
34% and 40%, respectively, in comparison with spheroids gen-
erated from cells transfected with GAP CTRL (ﬁgure 6E). In
addition, uc.158− silencing reduced tumour spheroid-based
migration in HepG2 cells (ﬁgure 6F). These data were also con-
ﬁrmed in CCA SW1 cells whose cell viability was dependent on
the Wnt pathway (see online supplementary ﬁgure S9).
Uc.158− acts as a competing endogenous RNA
Recent evidence suggests that T-UCRs may act as endogenous
competing RNAs (ceRNA).38 Thus, we searched for potential
binding sites for miRNAs in the uc.158− conserved sequence.
We shortlisted those miRNAs which are conserved across mouse
and human and show a binding site with a predicted ddG score
<−10 (see online supplementary ﬁgure S10 and table S7). We
proﬁled by NanoString analysis the global expression of
miRNAs in the mouse Apcﬂ/ﬂ HCC model. In the hypothesis
that uc.158− acts as ceRNA, we searched for miRNAs that were
downregulated in Apcﬂ/ﬂ versus Apc+/+ liver tissues (see online
supplementary table S7). Among these nine miRNAs, miR-615,
miR-193b and miR-346 were upregulated after inhibition of
uc.158− in HepG2 cells, with miR-193b showing the most
signiﬁcant increase and having higher values of expression
(ﬁgure 7A). Indeed, miR-193b was shown to be downregulated
in human HCC.39 40 We observed downregulation of miR-193b
also in human CCA tissues in comparison with matched
adjacent non-neoplastic tissues (see online supplementary
ﬁgure S11). miR-193b was found to be overexpressed in Huh-7
versus HepG2 cells (in line with uc.158− expression) (ﬁgure
7B). Enforced expression of uc.158− in Huh-7 cells induced
Figure 7 miR-193b expression is
dependent on uc.158− expression.
HepG2 cells were transfected in
100 mm dishes for 48 hours, and RNA
extracted to assess microRNA
expression by TaqMan assays. Bars
represent mean±SD of three
experiments. (B) miR-193b expression
was assessed in Huh-7 and HepG2
cells. Bars represent logarithmic
expression of miR-193b in Huh-7
versus HepG2. In three independent
experiments, miR-193b expression was
higher in Huh-7 in comparison with
HepG2. (C) Huh-7 cells were
transfected with a vector
overexpressing uc.158− or an empty
vector for 48 hours. Expression of
uc.158− and miR-193b was assessed
by real-time PCR. Bars represent the
logarithmic expression of ncRNAs in
cells transfected with uc-158− vector
compared with empty vector. The
downregulation of mR-193 is
quantitatively comparable with the
upregulation achieved in panel A. (D)
HepG2 cells were transfected with
GAPMER control or GAP1 alone or in
association with anti-miR-193b, and
cell viability assessed by CellTiter-Blue
at 48 hours. Bars represent mean±SD
of six replicates. (E) Sera were
collected from patients with
hepatocarcinoma (HCC) naïve for any
treatment (n:10), and microRNA
extracted using ﬁxed starting volume.
miR-193b was assessed by TaqMan
assay. χ2 test was used to assess the
correlation between miR-193b and
alpha-fetoprotein (AFP) groups.
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downregulation of miR-193b (ﬁgure 7C). Co-transfection of
GAP1 and anti-miR-193b could rescue the biological effect of
uc.158− inhibition on cell viability (ﬁgure 7D). We then looked
at the level of miR-193b in the sera of patients with HCC
(n:10) who were naive for any treatment. Patients with low cir-
culating miR-193b had mainly alpha-fetoprotein (AFP) negative
tumours, in line with previous reports of observed lower levels
of AFP in CTNNB1-mutated HCC41 (ﬁgure 7E).
DISCUSSION
It is becoming clear that a large number of lncRNAs have a
determining role in regulating normal cell physiology as well as
a variety of diseases including cancer.42 T-UCRs are long
ncRNAs that harbour ultraconserved elements and are altered in
human carcinomas. Despite some evidence suggests that DNA
methylation and miRNA-mediated regulation may be respon-
sible for their modulation,19 20 the mechanisms of T-UCR
deregulation have been poorly explored. In these studies, we
showed that T-UCRs may act downstream of key signalling
routes, such as the Wnt pathway, and drive cancer cell growth.
Wnt/β-catenin signalling is a key driver in about half of liver
cancers, and growing evidence is suggesting that ncRNAs are
mediators of this pathway.17 43 We provide the ﬁrst evidence
that T-UCRs can be dependent on Wnt activation in a species-
conserved fashion. In addition, our studies showed that uc.158−
is activated only in cancer cells, suggesting it may be speciﬁc for
Wnt activation that should be targeted for an antitumoural
effect. Indeed, Wnt inhibitor exploitation has been limited by
toxicity, and activation of the Wnt pathway in cirrhotic liver
may preclude the use of these drugs in patients with liver
cancer. Conversely, the identiﬁcation of a cancer-speciﬁc media-
tor of the pathway may improve the potential of designing novel
and more selective drugs. Interestingly, we have shown that
molecular traits, such as overexpression of uc.158−, may be
present across tumour types independently on site of origin.
These ﬁndings inform us that T-UCRs may either be used as
tissue-speciﬁc biomarkers, as in the case of TUC338,25 or may be
commonly deregulated across tumour types, such as uc.158−.
Inclusion criteria with regard to tumour origin (ICC vs ECC) are
still a debateable question in the design of clinical trials in CCA.
However, based on these studies, we may suggest that clinical
trials should be designed on the bases of molecular and genomic
features instead of tumour site, and may even include ICC and
HCC for selective drugs that target commonly deregulated path-
ways. As per the reason why uc.158− is aberrantly deregulated
in malignant hepatocytes and cholangiocytes, we may speculate
that uc.158− overexpressing hepatic cancer stem cells may give
rise to speciﬁc subtypes of HCC and CCA in the presence of
Wnt pathway. However, we cannot exclude that the plasticity
of mature hepatocytes to differentiate in cholangiocytes may
justify some common traits acquired during liver carcinogen-
esis.44 45 Another potential explanation relies on the evidence
that stroma is an important Wnt activator even in tumours,
such as CCA, that lack CTNNB1 mutations.27 35 Thus, further
studies are warranted to explore the involvement of the
stroma-induced activation of uc.158− driven carcinogenesis.
The mechanism of function of T-UCRs is still not clearly elu-
cidated. Previous evidence suggests that they may act as decoy
molecules for miRNAs.38 We provided data in support of this
hypothesis. We have previously shown that miR-193b mediates
apoptosis through targeting of mcl-1,12 and the overexpression
of uc.158− in HCC nicely ﬁts with these data as well as with
the previous work that found downregulation of miR-193b in a
subgroup of HCCs.39 40 It is increasingly recognised that cancer
cells rely on a complex network of transcripts generated from
coding and non-coding genes, and that interplay of different
RNA classes drives cancer progression more than a single aber-
ration.46 However, identiﬁcation of a single molecule represent-
ing the activation of a network may prove more useful for the
identiﬁcation of therapeutic targets and for the implementation
of screening technologies to be adopted for targeted therapy.
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